A new paper published in Medicine suggests that Heat shock proteins CPN10, CPN60, and CPN70 could act as biomarkers for bipolar disorder (BD). Moreover, CPN60 serum levels could act as a biomarker to specify which BD patients have abnormal activity of the hypothalamic-pituitary-adrenal (HPA) axis.
US regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns. The digital pill approved Monday combines two existing products: the former blockbuster psychiatric medication Abilify—long used to treat schizophrenia and bipolar disorder—with a sensor tracking system first approved in 2012.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.